EverHint – EMA 10 + Price + MACD – Top 15 Signals for Aug 19, 2026
Excerpt: 15 signals (from 35 total). Healthcare leads (10). price range $6-$1162. 1 with insider buying.
What This Signal Is
Experimental strategy combining price crossing above EMA10 from below with MACD Line crossing above Signal Line from below. Both conditions must occur on the same day for a signal, providing double confirmation and higher-quality setups.
Entry Criteria:
- Buy: Price > EMA10 AND MACD line crosses above signal line
- Sell: Price < EMA10 AND MACD line crosses below signal line
- Minimum ADV: $40M (liquidity filter)
- Earnings buffer: 7 days pre/post earnings
- Fresh signal: All conditions met on today's close
Holding period: 1-3 weeks | Risk level: Medium-High
Market Context
Equity markets are trading in a constructive, low-volatility environment, with all three major indices posting modest gains and the VIX declining sharply to 14.89. A VIX reading in this range signals that options markets are pricing in relatively calm conditions, which tends to compress intraday price swings and reduce the frequency of false breakouts. For momentum-based strategies like EMA/MACD crossover systems, this is a double-edged environment — trending moves tend to be more sustained and reliable, but the reduced volatility can also mean smaller profit ranges on individual signals.
The broad-based advance across the S&P 500, Nasdaq, and Dow Jones suggests healthy risk appetite without any single segment dominating, pointing to a balanced rather than speculative rally. In this kind of steady, low-fear tape, EMA-10 crossovers are more likely to align with genuine short-term trend shifts rather than noise-driven whipsaws. MACD confirmation adds an additional layer of signal quality here, as momentum is more likely to persist when volatility is contained and institutional participation is steady across sectors.
Healthcare leading the signal count is a notable rotation cue. Defensive sectors like Healthcare tend to attract capital when investors seek stability within an otherwise risk-on environment — suggesting some underlying caution beneath the surface optimism. This rotation dynamic supports a selective approach: signals from a sector with strong relative interest may carry higher conviction, while broader market signals should be monitored for signs of momentum fading if volatility continues to compress further.
🟢 Buy Signals (15 of 35 total)
Ranked by RSI (lower RSI = more oversold for buy signals)
| # | Ticker | Company | Sector | Price | Insider | MCap |
|---|---|---|---|---|---|---|
| 1 | ACN | Accenture plc | Technology | $183.34 | — | $112.2B |
| 2 | AFRM | Affirm Holdings, Inc. | Technology | $77.33 | — | $25.9B |
| 3 | ASND | Ascendis Pharma A/S | Healthcare | $259.62 | Buy +$222,219 | $16.1B |
| 4 | BLDR | Builders FirstSource, ... | Industrials | $72.55 | — | $7.8B |
| 5 | BRKR | Bruker Corporation | Healthcare | $58.65 | — | $8.9B |
| 6 | CBRE | CBRE Group, Inc. | Real Estate | $155.06 | — | $44.9B |
| 7 | COIN | Coinbase Global, Inc. | Financial Services | $160.20 | — | $42.3B |
| 8 | COUR | Coursera, Inc. | Consumer Defensive | $5.85 | — | $1.1B |
| 9 | CPNG | Coupang, Inc. | Consumer Cyclical | $16.66 | — | $29.9B |
| 10 | CWST | Casella Waste Systems,... | Industrials | $92.85 | — | $5.8B |
| 11 | DHR | Danaher Corporation | Healthcare | $211.50 | — | $148.7B |
| 12 | DNLI | Denali Therapeutics Inc. | Healthcare | $25.69 | — | $4.1B |
| 13 | EL | The Estée Lauder Comp... | Consumer Defensive | $98.01 | — | $35.4B |
| 14 | FICO | Fair Isaac Corporation | Technology | $1161.59 | — | $25.1B |
| 15 | FMC | FMC Corporation | Basic Materials | $10.81 | — | $1.4B |
Field Notes
Sector concentration: Healthcare (10), Consumer Cyclical (8), Technology (4)
Insider buying (7d): ASND (Ascendis Pharma A/S, +$222,219)
Data coverage: 2.9% insider (7d), 0.0% congressional (30d), 0.0% earnings, 8.6% news (7d)
Peer Analysis
ASND (Ascendis Pharma A/S): Leads 5 peers: IONS ($60.80), BBIO ($83.95), RVMD ($214.66), ROIV ($37.40), SMMT ($13.11)
FICO (Fair Isaac Corporation): Leads 5 peers: CLS ($301.36), GRMN ($295.67), NOK ($10.12), TEAM ($174.23), TTD ($13.54)
Recent Headlines
ACN (Accenture plc)
- Is It Too Late to Buy Accenture PLC (ACN) After 5.9% Rally? GF Value Says Undervalued
- Could Artificial Intelligence Be Accenture's Savior?
- Accenture (ACN) Dips More Than Broader Market: What You Should Know
AFRM (Affirm Holdings, Inc.)
- Cramer Warns Fintech Bulls: These Three Stocks Are Priced for Perfection
- SoFi Climbs 6%, Upstart Jumps 8%, Affirm Rises 7% as Fintech Names Rebound With Bond Market Catalyst
- Klarna Craters 19% on Guidance Cut While Affirm, PayPal Shrug It Off
- Should You Forget Big Banks and Bet on a Fintech Instead?
- Affirm Holdings (AFRM) Dips More Than Broader Market: What You Should Know
- Affirm to participate in upcoming investor conferences
ASND (Ascendis Pharma A/S)
- Eyconis Announces Initiation of First-in-Human Clinical Trial of EYC-0305 in Treatment-Naïve Wet Age-Related Macular Degeneration Patients
Vlad's Take
Today's signals: Strong sector concentration in Healthcare (10 signals) suggests sector-specific rotation. 1 signal with insider buying adds conviction.
Independent, data-driven signals.
No hype. No promotions. Just experimental market research from EverHint.
This is not financial advice. Market conditions change rapidly.
Do your own due diligence.
See https://www.everhint.com/disclaimer/ and https://www.everhint.com/faqs/
📢 If you found this useful, a quick like, share, or subscribe keeps EverHint moving forward.